NeutralLOW severityHealthcare & Pharma2h ago

McKesson EVP, CIO and CTO Francisco Fraga sells $630,000 in stock

McKesson EVP, CIO and CTO Francisco Fraga sells $630,000 in stock — $MCK one-month chart
$MCK daily closes over the past month · Wook of Wall Street artwork from market data
WOOKAI ASSISTANTREADY
WOOK AIASK ANYTHING · NEVER ADVISES

Ask about MCK. Get explanations, comparisons and calculations with the source lookups shown.

Wook analysis

What it means

Key points
  • What to watch: The headline hangs on one number ($630,000) — one data point is a snapshot, so the trailing trend is the context it needs.
  • How the stock is trading: $MCK +0.24% in the latest session.
  • Timing: It landed during trading hours — the market got to read it live, so the session move beside it may already carry the reaction.
Amount$630,000

Where the stock stands

$MCK last changed hands at $1,072.00, +0.24% on the session, 4.4% below its 52-week high of $1,121.50 and 48% above its low of $723.68 — in the upper part of the range. Over the year it has ranged 55% from low to high: a wide band — moves of several percent in a week come with the territory. These are latest-session quotes, not live prices — the live tape is on the $MCK page.

How much coverage it is getting

In the last 30 days Wook has filed 5 stories about $MCK — 4 of them this week. At its 30-day pace you would expect about 1 a week, so this week is running well ahead of normal; the press has found a reason to keep writing. Across those stories 2 read bullish, 3 neutral and 0 bearish — mostly headline writers keeping a straight face. This one reads neutral, so it sits squarely with the crowd. 3 of the 5 (60%) came from Investing.com itself, so the count says as much about how often Investing.com hits publish as about how much attention there is — the other outlets are the better gauge. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.

The bigger picture

Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. On Wook's supply-chain scanner, Health Care reads watch today — early signs of strain worth keeping an eye on.

What to watch next

The $MCK page has the full chart, the filings and the valuation model behind every figure here. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. Wook AI, above, can pull live figures and run the numbers on request — how far $MCK is from its high, or how this week's coverage compares.

How this analysis was made

Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $MCK. It carried $630,000, shown as published and not recalculated. The publisher gave no preview text, and nothing has been written in to fill the gap.

The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.

Discussion

No one has weighed in yet. Start the discussion on this story.

What happened after this published

Investing.com published this on November 5, 2026. $MCK has moved -1.08% ($1083.66 to $1072.00). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.

Headline and link are attributed to Investing.com. Wook of Wall Street is an independent research tool and is not affiliated with Investing.com. Nothing here is financial advice or a recommendation — research and educational content only.

Choose what this browser shares. Essential sign-in and security cookies stay on.

Read the privacy policy